poisar

Filings · News reference

Editas Medicine Files Prospectus For Offering $400M Mixed Shelf

BenzingaBenzinga Newsdesk

-SEC.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncUnknown

    Lyora Therapeutics Launches With Seed Funding to Propel Its Biologically Validated Pipeline of Genetic Medicines to Treat Inherited Retinal Diseases

    Lyora Therapeutics, a new biotech company focused on genetic medicines for inherited retinal diseases, launched with $2.5 million in seed funding. The company's lead programs include LYA-101 for retinitis pigmentosa and LYA-102 for Usher Syndrome Type 2, with plans to submit an IND for LYA-101 within 18 months. The company is led by experienced executives from major genetic medicine firms and co-founded by renowned ophthalmology researchers.

    Read original at globenewswire-inc